Skip Nav Destination
Close Modal
Update search
Filter
All
- All
- Title
- Author
- Author Affiliations
- Full Text
- Abstract
- Keyword
- DOI
- ISBN
- EISBN
- ISSN
- EISSN
- Issue
- Volume
- References
Filter
All
- All
- Title
- Author
- Author Affiliations
- Full Text
- Abstract
- Keyword
- DOI
- ISBN
- EISBN
- ISSN
- EISSN
- Issue
- Volume
- References
Filter
All
- All
- Title
- Author
- Author Affiliations
- Full Text
- Abstract
- Keyword
- DOI
- ISBN
- EISBN
- ISSN
- EISSN
- Issue
- Volume
- References
Filter
All
- All
- Title
- Author
- Author Affiliations
- Full Text
- Abstract
- Keyword
- DOI
- ISBN
- EISBN
- ISSN
- EISSN
- Issue
- Volume
- References
Filter
All
- All
- Title
- Author
- Author Affiliations
- Full Text
- Abstract
- Keyword
- DOI
- ISBN
- EISBN
- ISSN
- EISSN
- Issue
- Volume
- References
Filter
All
- All
- Title
- Author
- Author Affiliations
- Full Text
- Abstract
- Keyword
- DOI
- ISBN
- EISBN
- ISSN
- EISSN
- Issue
- Volume
- References
NARROW
Format
Subjects
Journal
Article Type
Issue Section
Date
Availability
1-4 of 4
Keywords: Durvalumab
Close
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Sort by
Journal Articles
Subject Area:
Oncology
Margherita Rimini, Silvia Foti, Silvia Camera, Federico Rossari, Francesco Vitiello, Federica Lo Prinzi, Luca Aldrighetti, Francesco De Cobelli, Federica Pedica, Paolo Giorgio Arcidiacono, Mara Persano, Stefano Cascinu, Andrea Casadei-Gardini
Journal:
Oncology
Oncology 1–22.
Published Online: 06 December 2024
... a survival benefit with durvalumab plus gemcitabine and cisplatin in patients with advanced biliary tract cancer (BTC). To understand this combinationʼs real-world efficacy and tolerability, we conducted a retrospective analysis of its first-line treatment outcomes. Methods: We included patients...
Journal Articles
Subject Area:
Oncology
Yasutoshi Fujii, Tomokazu Kawaoka, Yuki Shirane, Ryoichi Miura, Hikaru Nakahara, Kenji Yamaoka, Shinsuke Uchikawa, Hatsue Fujino, Atsushi Ono, Eisuke Murakami, Daiki Miki, Nelson Clair Hayes, Masataka Tsuge, Yuko Nakamura, Kazuo Awai, Shiro Oka
Journal:
Oncology
Oncology 1–6.
Published Online: 11 November 2024
...Yasutoshi Fujii; Tomokazu Kawaoka; Yuki Shirane; Ryoichi Miura; Hikaru Nakahara; Kenji Yamaoka; Shinsuke Uchikawa; Hatsue Fujino; Atsushi Ono; Eisuke Murakami; Daiki Miki; Nelson Clair Hayes; Masataka Tsuge; Yuko Nakamura; Kazuo Awai; Shiro Oka Introduction: Durvalumab plus tremelimumab combination...
Journal Articles
Udit Nindra, Victoria Bray, Deme Karikios, Mohsen Shafiei, Shalini Subramaniam, Pei Ding, Steven Kao, Abhijit Pal
Journal:
Oncology
Oncology (2024) 102 (8): 732–736.
Published Online: 17 January 2024
... (ASCO) guidelines recommend consolidation durvalumab for all patients with unresectable stage III NSCLC, irrespective of their PD-L1 expression or driver mutation status. The European Society of Medical Oncology (ESMO) differs, with consolidation durvalumab only recommended in those patients whose...
Journal Articles
Subject Area:
Oncology
David Hong, Drew Rasco, Michael Veeder, Jason J. Luke, Jason Chandler, Ani Balmanoukian, Thomas J. George, Pamela Munster, Jordan D. Berlin, Martin Gutierrez, Alain Mita, Heather Wakelee, Selda Samakoglu, Shanhong Guan, Isaiah Dimery, Thorsten Graef, Erkut Borazanci
Journal:
Oncology
Oncology (2019) 97 (2): 102–111.
Published Online: 21 June 2019
... ibrutinib plus durvalumab, a PD-L1-targeting antibody, in patients with relapsed/refractory solid tumors. Methods: This open-label, multicenter, phase 1b/2 study enrolled previously treated patients with stage III/IV pancreatic adenocarcinoma, breast cancer, or non-small cell lung cancer (NSCLC). Phase 1b...